Q2 26/27

Sun Pharma Advanced Research Company (SPARC) Q2 26/27 earnings summary

Event summary combining transcript, slides, and related documents.

Q2 26/27 earnings summary

2 Nov, 2026

Q2 FY27 revenue from operations was ₹3,003 lakh standalone and consolidated; H1 revenue was ₹6,995 lakh, with net losses of ₹2,458 lakh and ₹4,498 lakh, respectively, in Q2.
The Board approved unaudited standalone and consolidated Q2 and H1 results; auditors’ limited reviews found no matters indicating material misstatement.

Standalone Q2 revenue from operations was ₹3,003 lakh versus ₹786 lakh YoY; total income was ₹5,365 lakh versus ₹787 lakh.
Consolidated Q2 revenue from operations was ₹3,003 lakh versus ₹786 lakh YoY; total income was ₹5,365 lakh versus ₹787 lakh.
Standalone H1 revenue was ₹6,995 lakh versus ₹1,750 lakh YoY; net loss narrowed to ₹4,556 lakh from ₹12,800 lakh.
Consolidated H1 revenue was ₹6,995 lakh versus ₹1,750 lakh YoY; net loss narrowed to ₹4,498 lakh from ₹12,760 lakh.

Pharmaceutical Research and Development was the sole reportable business segment.

Partial view of Summaries dataset, powered by Quartr API

AI can get things wrong. Verify important information.

All investor relations material. One API.